Novo: Back From The Dead
Novo Nordisk has rebounded over 40% after a sharp 2025 sell-off, driven by renewed optimism for its oral Wegovy launch. Valuation reset, strong technicals, and an underappreciated pipeline make NVO attractive, especially as it transitions from a single-product to a platform company. Upcoming Q4 results are pivotal, with investor focus on oral Wegovy uptake, manufacturing capacity, and margin trajectory amid competitive and political pressures.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and up to $25 billion projected for 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk expands diabetes cell therapy partnership with Aspect Biosystems
Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have struck a partnership to develop cell-based treatments for diabetes.
Is Novo Nordisk's Oral Wegovy Driving Strong Early US Demand Already?
NVO shares jump 9.1% as early U.S. prescriptions for oral Wegovy show strong first-week demand after its early January launch.
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid' launch
Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the launch of the company's new GLP-1 pill for obesity in the U.S. In a Friday note, TD Cowen analysts called it a "solid start" but cautioned that they need to see more data to fully assess what early demand is like for the Wegovy pill.
Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch
Novo Nordisk's Wegovy pill hit 3,071 U.S. prescriptions in the first four days after its launch, IQVIA data shared by analysts on Friday showed, as investors closely watch to see if the firm can ram home its first-mover advantage against rival Eli Lilly in a competitive weight-loss market.
Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss
Britain's regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.
Novo shares jump 7% ahead of US prescription data for Wegovy pill
Shares of Novo Nordisk rose 7% on Friday, touching their highest level since September, and were among the top gainers in Europe, ahead of U.S. prescription data expected from analysts on the Danish drugmaker's Wegovy pill.
Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors
Novo Nordisk (NVO) concluded the recent trading session at $58.98, signifying a -1.12% move from its prior day's close.
Novo Nordisk Soars 19% in a Month: How Should You Play the Stock?
NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.
Novo Nordisk CEO: Wegovy not only reduces your weight, but it also shows cardiovascular benefits
Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
